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Glutamate Transporters in the Blood-Brain 
Barrier
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Helle Sønderby Waagepetersen, and Birger Brodin
Abstract The amino acid L-glutamate serves a number of roles in the central ner-
vous system, being an excitatory neurotransmitter, metabolite, and building block in 
protein synthesis. During pathophysiological events, where L-glutamate homeosta-
sis cannot be maintained, the increased brain interstitial fluid concentration of 
L-glutamate causes excitotoxicity. A tight control of the brain interstitial fluid 
L-glutamate levels is therefore imperative, in order to maintain optimal neurotrans-
mission and to avoid such excitotoxicity. The blood-brain barrier, i.e., the endothe-
lial lining of the brain capillaries, regulates the exchange of nutrients, gases, and 
metabolic waste products between plasma and brain interstitial fluid. It has been 
suggested that brain capillary endothelial cells could play an important role in 
L-glutamate homeostasis by mediating brain-to-blood L-glutamate efflux. Both 
in  vitro and in  vivo studies have demonstrated blood-to-brain transport of 
L-glutamate, at least during pathological events. A number of studies have shown 
that brain endothelial cells express excitatory amino acid transporters, which may 
account for abluminal concentrative uptake of L-glutamate into the capillary endo-
thelial cells. The mechanisms underlying transendothelial L-glutamate transport are 
however still not well understood. The present chapter summarizes the current 
knowledge on blood-brain barrier L-glutamate transporters and the suggested path-
ways for the brain-to-blood L-glutamate efflux.
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1  Introduction
L-glutamate is one of the most common amino acids, a building block in protein 
synthesis and an important metabolite in intermediary metabolism linking carbo-
hydrate and amino acid metabolism. L-glutamate is also considered to be the 
most abundant excitatory neurotransmitter in the vertebrate brain (Zhou and 
Danbolt 2014). L-glutamate is stored in vesicles in the synapses of glutamatergic 
neurons and released into the synaptic cleft upon nerve stimulation. The trans-
mitter is rapidly removed from the synaptic cleft and the brain interstitial fluid 
(ISF) by the concerted actions of glutamate transporters in neurons and astro-
cytes. Prolonged elevated concentrations of L-glutamate in the ISF are highly 
cytotoxic since continued and excessive stimulation of glutamate receptors will 
cause abnormal high intracellular calcium levels in neurons, followed by activa-
tion of a number of enzyme cascades and, eventually, cell death. This phenome-
non has been termed excitotoxicity (Nakanishi 1992; Rothman 1984) and occurs 
during a number of pathophysiological conditions (Gillessen et  al. 2002; 
Leibowitz et al. 2012).
The blood-brain barrier, i.e., the endothelium of the brain capillaries, acts as a 
gatekeeper between the blood and the brain ISF. One major role of the brain endo-
thelium is to separate the blood plasma constituents and the ISF, since the blood 
concentration of L-glutamate is 10–100-fold higher than in the brain, and free pas-
sage across the barrier would cause excitotoxicity. A number of studies have indi-
cated that the brain endothelium might also play an active role in the regulation of 
brain L-glutamate concentrations beyond just being a static barrier to the peripheral 
circulation. Brain endothelial cells express excitatory amino acid transporters 
(EAAT's) and have been proposed to efflux L-glutamate via the concerted actions of 
abluminal (brain-facing) and luminal (blood-facing) transport proteins (Boyko et al. 
2014; Roberts et al. 2014; Teichberg et al. 2009; Campos et al. 2011a; Cohen- Kashi- 
Malina et al. 2012; Helms et al. 2012; Lyck et al. 2009).
Previous reviews of the field have focused on the role of possible blood-to-brain 
transport of L-glutamate originating from dietary monosodium glutamate (Hawkins 
2009), on EAATs (Danbolt et  al. 2016) and blood L-glutamate scavenging 
(Teichberg et  al. 2009), on possible therapeutic applications of blood glutamate 
scavenging (Castillo et  al. 2016) and on potential clinical relevance of BBB- 
glutamate efflux (Cederberg et al. 2014). The aim of the present chapter is to supply 
an overview of L-glutamate transport proteins in the brain capillary endothelium, as 
well as their role in uptake and transendothelial transport. Possible metabolism of 
glutamate in the endothelial cells and astrocytes will be discussed. Finally, we will 
address the proposed concept of “glutamate scavenging” and point toward areas 
which in our point of view warrants further investigations.
H.C.C. Helms et al.
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2  Early Studies on Glutamate Transport Across Brain 
Endothelium
There is a large difference between L-glutamate concentrations in blood and in 
brain tissue interstitial fluid. Free plasma concentrations have been estimated to be 
in the range of 30–90 μM (Hagenfeldt and Arvidsson 1980; Graham et al. 1995), 
whereas erythrocyte concentrations are in the range of 280 μM (Hagenfeldt and 
Arvidsson 1980) to 450 μM (Divino Filho et al. 1997), thus giving whole blood 
concentrations of L-glutamate at approximately 140 μM taking the volume frac-
tions into consideration (Hagenfeldt and Arvidsson 1980).
Brain ISF L-glutamate concentrations are in the lower μmolar range. Sampling 
and analysis of brain ISF from the resting undisturbed brain is not trivial, but micro-
dialysis studies have indicated values of 0.1–3 μM (Persson and Hillered 1992). 
Estimations of L-glutamate concentrations in the cerebrospinal fluid yield values in 
a similar range, i.e., 0.5–3 μM (Iijima et al. 1978; Spink et al. 1986).
The large concentration difference of L-glutamate across the blood-brain barrier 
could indicate that the brain endothelial cells have a very low permeability for 
L-glutamate, an active transport of L-glutamate from brain ISF to blood, a fast 
metabolism of L-glutamate, or a combination of these, along with a fast metabo-
lism/clearance of L-glutamate in the ISF by astrocytes and neurons (Schousboe 
et al. 2014; Waagepetersen et al. 2005).
The concentrations of L-glutamate in brain endothelial cells have been estimated 
to be approximately 750 nmol g−1 (Cardelli-Cangiano et  al. 1981), equivalent to 
approximately 785 μM (assuming an endothelial cell density of 1.048 g ml−1 (Pries 
et al. 2000)). Considering that the free L-glutamate concentration is ~60 μM in the 
blood, the concentration gradient will favor transport from the cell cytosol to the 
blood and not favor uptake from blood to cell. Early studies on blood-to-brain trans-
port of tracer amounts of radiolabeled glutamate in rats showed a low brain uptake 
(Oldendorf 1971; Sershen and Lajtha 1976), as measured by the brain uptake index 
(BUI) method. The uptake of radiolabeled tracer was shown to be inhibited by 
excess non-labeled L-glutamate, indicating that the transport from blood to brain 
took place via a saturable carrier-type mechanism (Oldendorf and Szabo 1976). 
These estimates were, however, based on unidirectional influx values.
Despite the cell-to-blood concentration gradient of L-glutamate, there would still 
exist a unidirectional isotope flux in the blood-to-cell direction, as observed by 
Oldendorf and Szabo, but not a net uptake (Oldendorf and Szabo 1976). In sum-
mary, the initial studies indicated the presence of a carrier mechanism for 
L-glutamate in the luminal membrane of the brain endothelium but also a large 
gradient for L-glutamate transport from plasma to cell, indicating either that the 
observed fluxes only were indicative of unidirectional influx (plasma to cell) in a 
situation where a net efflux was occurring or that the thermodynamically “uphill” 
transport of L-glutamate from plasma to cell was coupled to a dissipation of a con-
centration gradient (either a co- or counter transport) or a pump-type transporter 
(driven by hydrolysis of ATP). This issue was addressed by Drewes and colleagues, 
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who showed a net efflux of L-glutamate from the brain to the blood in studies on 
perfused dog brains (Drewes et al. 1977). In brief, the author’s measured concentra-
tions of amino acids in the arterial and venous perfusates using chromatography 
techniques, and net movements of amino acids, were calculated from the concentra-
tion differences in arterial and venous concentrations. They observed a net efflux of 
L-glutamate from the brain in the order of ~1 μmol 100 g brain−1 min−1 under basal 
conditions (Drewes et al. 1977). On the basis of these data, Pardridge suggested that 
an active L-glutamate brain-to-blood efflux system was present and functional 
under resting conditions in the brain capillary endothelium (Pardridge 1979). 
Hutchison and colleagues investigated uptake kinetics of L-glutamate into isolated 
rat brain capillaries (Hutchison et al. 1985). They demonstrated that a high-affinity 
(KM of approximately 2 μM), temperature-dependent, and ouabain-sensitive 
L-glutamate uptake system was present in the capillaries, which could account for 
the previously observed brain efflux. This was further supported by Hosoya et al., 
who performed intracerebral microinjections of radioactive L-glutamate, 
L-aspartate, and D-aspartate in rats (Hosoya et al. 1999). They demonstrated rapid 
clearance from the brain of L-glutamate and L-aspartate, which correlated with the 
appearance of the two isotopes in jugular vein samples, whereas D-aspartate stayed 
in the brain compartment. Hosoya et al. used thin layer chromatography to verify 
that at least the main part of the appearing radioactivity in the blood originated from 
intact L-aspartate/L-glutamate (approximately 70% and 84%, respectively) (Hosoya 
et al. 1999). Initially, this efflux was not believed to be associated with EAAT trans-
porters, partly because of lack of D-aspartate efflux and partly because immunola-
beling studies had not shown EAAT1 and EAAT2 expression in rat brain endothelial 
cells (Hosoya et al. 1999; Chaudhry et al. 1995; Lehre et al. 1995). However, in the 
recent decades, evidence has accumulated that EAATs are present in brain capillary 
endothelial cells and may take part in the brain L-glutamate efflux (see sections 
below).
3  Expression of Glutamate Transporters in the Brain 
Capillary Endothelium
3.1  Transporters of Glutamate
Glutamate transporters are transmembrane proteins belonging to the solute carrier 
(SLC) family 1, SLC 7, SLC 17, or SLC25 (see Table 1) (Fotiadis et al. 2013; Kanai 
et al. 2013; Palmieri 2013; Reimer 2013; Hegedus and Taale 2013). The SLC1 fam-
ily consists of seven members, with five members being excitatory amino acid 
transporters (EAATs) transporting glutamate and aspartate and two members being 
alanine, serine, and cystine (ASC) transporters transporting alanine, serine, cystine, 
and threonine (see Table 1 (Kanai et al. 2013; Hegedus and Taale 2013)). The Km 
values described for L-glutamate transport by EAAT1 are in the range of 7–20 μM; 
H.C.C. Helms et al.
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Table 1 Transporters of glutamate
Gene Protein
Main cell types 
in the CNS Cellular localization References
SLC1A1 EAAT3
(EAAC1)
Neurons and 
substantia nigra, 
red nucleus, 
hippocampus, 
cerebral cortical 
layers
Plasma membrane of 
postsynaptic neurons
Shashidharan et al. 
(1994),
Kanai and Hediger 
(1992), Kanai et al. 
(1994), Rothstein 
et al. (1994)
SLC1A2 EAAT2
(GLT-1)
Astrocytes
Glia cells
Plasma membrane Pines et al. (1992), 
Danbolt et al. (1992)
SLC1A3 EAAT1
(GLAST)
Glia cells 
Astrocytes
Plasma membrane Storck et al. (1992), 
Danbolt et al. (1994)
SLC1A6 EAAT4 Purkinje cell 
somas and 
dendrites
Plasma membrane Fairman et al. (1995), 
Lin et al. (1998)
SLC1A7 EAAT5 Retina Plasma membrane Arriza et al. (1997)
SLC7A11 xCT 
(associate 
with 4F2hc 
to form 
system xc-)
Brain (neurons, 
astrocytes, and 
glial cells) and 
spinal cord
Plasma membrane Kim et al. (2001), 
Jackman et al. (2010), 
Fogal et al. (2007)
SLC7A13 AGT-1 
(associate 
with rBAT 
as heavy 
chain)
Not expressed Basolateral plasma 
membrane in proximal 
straight tubules and 
distal convoluted 
tubules (Matsuo et al. 
2002) but apical in 
another study 
(Nagamori et al. 2016)
Blondeau (2002), 
Matsuo et al. (2002)
SLC17A6 VGLUT2 Small:
(0–500 μm2)
Medium:
(500–1300 μm2) 
DRG
Vesicular  membrane Malet et al. (2013), 
Aihara et al. (2000)
SLC17A7 VGLUT1 Medium:
(500–1300 μm2)
Large:
(1300–2900 
μm2) DRG
Vesicular membrane Malet et al. (2013), Ni 
et al. (1994)
SLC17A8 VGLUT3 Small:
(0–500 μm2)
Medium:
(500–1300 μm2) 
DRG
Vesicular membrane Malet et al. (2013), 
Takamori et al. (2002)
SLC25A12 AGC1 
(aralar)
Neurons in the 
brain stem and 
spinal cord
Mitochondrion inner 
membrane
del Arco and 
Satrustegui (1998), 
Ramos et al. (2003)
(continued)
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for EAAT2 and EAAT3, they are 12–18 μM and 8–30 μM, respectively. EAAT4 has 
the highest affinity reported for glutamate transport via EAATs with Km values in 
the range of 0.6–3.3 μM, while EAAT5 has the lowest affinity with Km values in the 
range of 61–63 μM (for references see (Danbolt et  al. 2016)). The uptake of 
L-glutamate via EAATs is indirectly dependent on the energy status of the cell since 
the translocation cycle includes cotransport of one molecule of L-glutamate with 
three sodium ions and one hydrogen ion and an exchange with one potassium ion 
(Levy et al. 1998; Zerangue and Kavanaugh 1996). The transport activity and direc-
tion is thus coupled to the sodium-potassium ATPase (Rose et al. 2009). SLC7 is the 
family of cationic amino acid transporters and glycoprotein-associated proteins. 
SLC7A11 is the light chain that coupled with the heavy chain 4F2hc forms system 
xc− that is a cystine/L-glutamate exchanger and SLC7A13 which associate with 
rBAT as heavy chain forming an L-aspartate/L-glutamate exchanger, apparently not 
expressed in the brain (SLC tables). The SLC 17 family contains vesicular gluta-
mate transporters which are involved in glutamate accumulation in membrane vesi-
cles in presynaptic neurons. These transporters are electrogenic chloride-dependent 
glutamate transporters. The SLC25 family contains mitochondrial glutamate trans-
porters. SLC25A12 and SLC25A13 are calcium- and proton-dependent exchangers 
of cytoplasmic glutamate with mitochondrial aspartate which takes place across the 
inner mitochondrial membrane. SLC25A18 and SLC25A22 are proton-coupled 
glutamate transporters involved in glutamate transport across the inner mitochon-
drial membrane. In the context of glutamate transport across the brain endothelium, 
EAAT transporters are relevant to consider  (Table 2), acknowledging that both 
VGLUT and EAATs are important for overall glutamate levels in the healthy brain 
and in disease.
Table 1 (continued)
Gene Protein
Main cell types 
in the CNS Cellular localization References
SLC25A13 AGC2 
(citrin)
Limited to 
neuronal cluster
Mitochondrion inner 
membrane
Kobayashi et al. 
(1999), Del Arco et al. 
(2000), Contreras 
et al. (2010)
SLC25A18 GC2 Expressed in 
brain panels
Mitochondrion inner 
membrane
Fiermonte et al. 
(2002)
SLC25A22 GC1 Expressed in 
brain panels, 
and in 
developing 
human nervous 
system, notably 
in the 
hippocampus, 
cortex, and 
brainstem
Mitochondrion inner 
membrane
Fiermonte et al. 
(2002), Molinari et al. 
(2005)
DRG dorsal root ganglia
H.C.C. Helms et al.
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3.2  Expression of EAATs in Intact or Isolated Brain 
Capillaries
Chun and co-workers performed a proteomics study on freshly isolated mouse brain 
microvessel membranes, and, using multidimensional protein identification tech-
nology, they identified 1143 proteins of which 101 were membrane transporters of 
mainly the SLC family (Chun et al. 2011). The gene products of plasma membrane 
glutamate transporters Slc1a2 and Slc1a3 were among the most abundant transport-
ers, but also mitochondrial glutamate transporters from Slc25a22 and Slc25a18 
genes were found (Chun et al. 2011). Gene products of Slc17a7 and Slc1a1 were 
also identified with spectral counts above 5 (Chun et al. 2011). In contrast, Ushida 
and co-worker found 20 membrane transporters in human brain microvessels and 
found only EAAT1 and not EAAT3 protein amounts above the detection limit 
(Uchida et  al. 2011). In brain capillaries isolated from marmoset brain, EAAT1 
protein was found highly expressed (Hoshi et al. 2013). Moreover, a recent electron 
microscopy study by Roberts et al. showed a clear EAAT1 expression in brain capil-
lary endothelial cells from human postmortem cortex samples (Roberts et al. 2014). 
Brain capillaries from mice have been shown to have a high expression of EAAT3 
mRNA (Lyck et al. 2009; Daneman et al. 2010; Guo et al. 2012) as well as protein 
expression of EAAT1, EAAT2 and EAAT3 (although mainly subtypes 2 and 3) 
(Lecointre et  al. 2014). Freshly isolated bovine brain capillaries express EAAT1, 
EAAT2, and EAAT3 mRNA, whereas only EAAT1 has been detected at the protein 
level (Helms et al. 2012; O’Kane et al. 1999). Large quantities of EAAT1 mRNA 
(Shawahna et al. 2011) were found in human brain capillaries. These studies indi-
cate that EAATs are present in endothelial cells, even though a study on rat 
Table 2 Overview of EAAT subtype expression patterns in capillaries and capillary-derived cell 
cultures from different species
EAAT1 EAAT2 EAAT3 References
Capillaries 
or intact 
tissue 
preparations
mRNA B,H, M B, M M Helms et al. (2012), Lyck et al. 
(2009), Daneman et al. (2010), 
Guo et al. (2012), O’Kane et al. 
(1999), Shawahna et al. (2011)
Protein B, H, M, Ma M M Roberts et al. (2014), Helms et al. 
(2012), Chun et al. (2011), Uchida 
et al. (2011), Lecointre et al. 
(2014), O’Kane et al. (1999), 
Hoshi et al. (2013)
Cell culture mRNA B B, M Helms et al. (2012), Lyck et al. 
(2009)
Protein B, M, P, R M, P B, M, 
P, R
Campos et al. (2011a), Cohen-
Kashi-Malina et al. (2012), Helms 
et al. (2012), Lecointre et al. 
(2014)
B bovine, H human, M mouse, P porcine, R rat, Ma marmoset
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capillaries revealed little or no EAAT staining on the abluminal surface of brain 
capillaries (Chaudry et al. 1995). However the subtype specific expression pattern 
may vary between species. It has to be kept in mind that contamination by glial 
 tissue or remnants of astrocyte end feet may be a general concern as protein frag-
ments from these tissues will greatly affect conclusions made.
3.3  Expression and Functional Activity of Excitatory Amino 
Acid Transporters in Cultured Endothelial Cells 
and Vesicle Preparations
Abluminal sodium-dependent saturable uptake was initially demonstrated in mem-
brane vesicles from bovine brain endothelial cells (Lee et al. 1998). The uptake was 
attributed to EAATs through protein expression and uptake studies. The studies 
demonstrated expression of EAAT1, EAAT2, and EAAT3 in abluminal membrane 
vesicles as well as high-affinity uptake matching that of EAATs in other cell types 
(O’Kane et al. 1999). In cell cultures, EAAT3 seemed to be the main transporter in 
mouse brain endothelial cells (Lyck et  al. 2009; Lecointre et  al. 2014), whereas 
EAAT1 displayed the highest expression level in bovine endothelial cells co- 
cultured with rat astrocytes (Helms et al. 2012). Helms et al. showed that EAAT1 is 
the dominant abluminal L-glutamate transporter in this model (Helms et al. 2016). 
EAAT1, EAAT2, and EAAT3 were all present in cultured endothelial cells from rat 
and porcine brains although EAAT3 seemed to be expressed at a higher level than 
the other subtypes (Campos et al. 2011a; Cohen-Kashi-Malina et al. 2012).
3.4  The Luminal Glutamate Transport System
Early in vivo studies indicate the presence of a facilitative L-glutamate transporter 
at the luminal membrane of the endothelial cells. Uptake of L-glutamate from the 
blood circulation and into the brain was shown in rats after a carotid bolus injection 
of radiolabeled L-glutamate (Oldendorf and Szabo 1976). The putative transporter 
was named xG− (Christensen 1984) and was shown to be independent of sodium and 
inhibited by L-glutamate and L-aspartate (Oldendorf and Szabo 1976; Lee et  al. 
1998; Benrabh and Lefauconnier 1996). The transporter has not been cloned, and it 
is possible that an already known amino acid transporter facilitates the passage of 
the luminal membrane. The glutamate-cystine exchanger (xc) could be a candidate 
to a transporter which could efflux intracellular L-glutamate from the endothelial 
cells to the blood in exchange for cystine uptake. However, previous studies have 
shown no effects of cystine on luminal endothelial L-glutamate uptake (O’Kane 
et al. 1999; Benrabh and Lefauconnier 1996). In the mouse brain endothelial cell 
line, MBEC4A, xCT, and 4F2hc mRNA are expressed, and carrier-mediated cystine 
and glutamate uptake has been measured, although it may be difficult to distinguish 
H.C.C. Helms et al.
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luminal and abluminal uptake in cells cultured on the bottom of cell culture wells 
(Hosoya et al. 2002). In rat brain slices, a low-affinity L-glutamate transporter has 
been described (Balcar and Johnston 1972; Benjamin and Quastel 1976). This trans-
porter of L-glutamate was inhibited by L-glutamate, L-aspartate, and L-homocysteate 
(Cox et al. 1977), which matches the inhibition pattern observed for the xG− trans-
porter (Benrabh and Lefauconnier 1996). The low-affinity L-glutamate uptake has a 
KM of 1–2 mM (Balcar and Johnston 1972; Benjamin and Quastel 1976). This 
matches the KM value for L-glutamate in luminal membrane vesicles from bovine 
brain endothelium, as determined by Lee et al. (1998). Helms et al. found kinetic 
and inhibition patterns matching the presumed low-affinity glutamate transporter by 
measuring luminal glutamate uptake in cultured bovine brain endothelial cells 
(Helms et al. 2016). An experimental limitation to the study of exchanges may be to 
have appropriate intracellular glutamate levels in intact cell cultures in vitro and to 
functionally show the exchange mechanism via cystine uptake.
4  Glutamate Metabolism in Brain Endothelial Cells
Efficient uptake of glutamate into astrocytes is followed by synthesis of glutamine 
catalyzed by the cytosolic enzyme glutamine synthetase. Glutamine is excreted from 
the astrocytes and known to be taken up by neurons to be reused as precursor for neu-
rotransmitter glutamate as part of the glutamate-glutamine cycle. In addition, 
L-glutamate is extensively oxidatively metabolized in astrocytes, initially to 
α-ketoglutarate either via an oxidative deamination catalyzed by glutamate dehydro-
genase or an aminotransferase of which aspartate aminotransferase (AAT), alanine 
aminotransferase (ALAT), and branched chain aminotransferase (BCAT) have the 
highest activities in the brain (Danbolt 2001). The observed efflux across the blood-
brain barrier obtained using radiolabeled L-glutamate could therefore in theory be 
explained by uptake and metabolism in astrocytes and transport of labeled metabolites 
across the endothelial cells. Two studies tested the effect of glutamine synthetase inhi-
bition using methionine sulfoximine in endothelial/astrocyte co- cultures and found no 
effects on the transcellular L-glutamate transport (Cohen- Kashi- Malina et al. 2012; 
Helms et al. 2012). However, conversion to α-ketoglutarate and further oxidation of 
the radiolabeled L-glutamate may still result in radiolabeled metabolites, which would 
influence estimates of the transendothelial transport of L-glutamate, using radiolabel. 
Astrocytes are known to release lactate as product of glutamate oxidation, via malic 
enzyme catalyzed oxidation of malate to pyruvate and subsequently operation of lac-
tate dehydrogenase (Olsen and Sonnewald 2015). Another candidate is the TCA cycle 
intermediate citrate, which is also released from astrocytes (Westergaard et al. 1994). 
In agreement with this, citrate and lactate formed from exogenously applied gluta-
mate was found in the abluminal medium (where astrocytes are present) of a noncon-
tact co-culture of astrocytes and endothelial cells (Helms et al. 2016).
Alternatively, glutamate may be metabolized in the endothelial cells following 
EAAT-mediated uptake. Although endothelial cells in general are known to rely 
Glutamate Transporters in the Blood-Brain Barrier
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mostly on aerobic glycolytic energy production, Oldendorf et al. demonstrated a 
high density of mitochondria in brain endothelial cells (Oldendorf et  al. 1977). 
Interestingly, mitochondria and EAAT1 and EAAT2 co-localize in astrocytes, sup-
porting rapid glutamate oxidation and fueling of the energy requiring uptake by 
glutamate degradation (Pajecka et  al. 2015; Robinson and Jackson 2016). It has 
been suggested that endothelial cells may oxidize L-glutamate to fuel the 
 ATP- binding cassette (ABC) drug efflux transporters (Mann et  al. 2003). It was 
recently shown, using a noncontact co-culture of astrocytes and endothelial cells 
exposed to 13C glutamate in the abluminal medium, that glutamate is indeed oxida-
tively metabolized in the endothelial cells (Helms et al. 2016). This was evident 
from the 13C labeling of glutamate and the TCA cycle intermediates, α-ketoglutarate, 
succinate, and malate observed in the endothelial compartment. A complete oxida-
tive degradation of glutamate requires an initial oxidation of malate or oxaloacetate 
to pyruvate either via malic enzyme activity or the concerted action of phosphoenol-
pyruvate carboxykinase and pyruvate kinase, respectively. Pyruvate is next either 
reduced to lactate or decarboxylated to acetyl CoA. Lactate is released, whereas 
acetyl CoA is further processed to CO2 in the TCA cycle. The study demonstrated 
formation of pyruvate and further metabolism to lactate and acetyl CoA in the endo-
thelial cells. The relative extent to which glutamate was metabolized to acetyl CoA 
and further metabolized in the TCA cycle was higher in the endothelial cells com-
pared to the astrocytes. This may at least partly be explained by a low oxidative 
glucose metabolism in endothelial cells, and it supports an important role of gluta-
mate as an energy substrate for the endothelial cells. The complete oxidation of 
glutamate is in accordance with the expression of glutamate dehydrogenase in 
endothelial cells (Zhang et  al. 2014). The operation of glutamate dehydrogenase 
provides a net entrance of α-ketoglutarate to the TCA cycle, in contrast to amino-
transferases that involves another keto acid. Citrate, which is formed in the TCA 
cycle from the condensation of oxaloacetate and acetyl CoA, was released into the 
luminal medium and is together with lactate products of glutamate oxidation. In 
addition, a non-negligible amount of aspartate was found in the luminal medium 
most likely originating from endothelial metabolism. Net formation of aspartate is 
formed from glutamate via aspartate aminotransferase in combination with several 
oxidative steps in the TCA cycle converting α-ketoglutarate to oxaloacetate, a pro-
cess known as “the truncated TCA cycle” (Skytt et al. 2012). The operation of “the 
truncated TCA cycle” is also in line with a low oxidative glycolytic rate and avail-
ability of acetyl CoA in endothelial cells. Thus, metabolism of glutamate in endo-
thelial cells should be taken into account using radiolabeled glutamate to investigate 
transcellular processes.
As mentioned above, intact labeled L-glutamate was recovered in the blood after 
intracerebral injections in rats (Hosoya et al. 1999), indicating that some L-glutamate 
is transported intact through the cells. Alternatively, paracellular leakage of radiola-
beled L-glutamate following the injection may add to the explanation. However, the 
true balance between metabolism and transport of intact L-glutamate has not yet 
been fully established and warrants further investigations. The possible transport 
mechanisms are summarized in Fig. 1.
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5  Blood Glutamate Scavenging: Treatment Paradigm, 
Clinical Relevance, and Possible Involvement 
of Endothelial Excitatory Amino Acid Transporters
Based on the observations that L-glutamate can be transported from brain ISF to the 
blood in animal studies (Drewes et al. 1977; Hosoya et al. 1999) combined with 
observations of expression of EAATs in brain endothelial cells (O’Kane et al. 1999), 
it has been proposed that the blood-brain barrier can mediate clearance of 
L-glutamate and that this might be a mechanism to minimize the excitotoxic dam-
age which may occur under pathophysiological situations. However, the blood glu-
tamate levels of approximately 140 μM (Hagenfeldt and Arvidsson 1980; Graham 
et  al. 1995) limits the blood-brain-barrier-mediated L-glutamate clearance by 
Fig. 1 Glutamate transport and metabolism pathways in the neurovascular unit and how metabo-
lites may appear in the blood after transcellular transport. α-KG α-ketoglutarate, AT amino acid 
aminotransferase, AGC1 mitochondrial aspartate/glutamate carrier-1, EAAT excitatory amino acid 
transporter, GDH glutamate dehydrogenase, GLN glutamine, GLNase glutaminase, GLU 
L-glutamate, ISF interstitial fluid, LAC lactate, LDH lactate dehydrogenase, MCT-1 monocarbox-
ylic acid transporter-1, MPC1/2 mitochondrial pyruvate carrier-1/2, Pyr pyruvate, SNAT small 
neutral amino acid transporter, TCA tricarboxylic acid cycle, VGLUT vesicular glutamate trans-
porter, X? unknown luminal glutamate transporter (figure modified from (Cederberg et al. 2014) 
with permission)
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providing an unfavorable concentration gradient. The combination of endothelial 
EAAT expression and the relatively high blood glutamate levels leads to the concept 
of blood glutamate scavenging, where active lowering of blood glutamate concen-
trations is hypothesized to increase brain-to-blood transport of L-glutamate because 
of a more favorable concentration gradient from endothelium to blood (Gottlieb 
et al. 2003). This was initially demonstrated in rats, where lowering blood glutamate 
by intravenous injections of oxaloacetate and pyruvate caused lowering of gluta-
mate levels in the cerebrospinal fluid and increased presence of 3H-labeled gluta-
mate in the blood after intracerebroventricular injection (Gottlieb et al. 2003). This 
experiment demonstrated transport of glutamate from the cerebrospinal fluid to the 
blood, which is not directly comparable to transport across the blood-brain barrier, 
but the experiment inspired other investigations of similar concept regarding blood- 
brain- barrier-mediated efflux.
These experiments have shown beneficial effects of blood glutamate scavenging 
in rats after middle cerebral artery occlusion, closed head injury, subarachnoid 
hemorrhage, traumatic brain injury, paraoxon intoxication, and amyloid-beta toxic-
ity (Campos et al. 2011a; Zlotnik et al. 2012; Ruban et al. 2014; Boyko et al. 2012; 
Perez-Mato et  al. 2014; Zlotnik et  al. 2009; Zhang et  al. 2016) (for review see 
(Castillo et al. 2016)). Furthermore, blood levels of the endogenous enzyme aspar-
tate aminotransferase have been shown to correlate positively with lower infarct 
volume and decreased early neurological deterioration (END) after ischemic stroke 
in humans (Campos et al. 2011b). Scavenging of L-glutamate from the blood circu-
lation seems to be an effective treatment in animal models, and may hold clinical 
potential, but the exact clearance pathways from the brain to the blood are not yet 
clearly elucidated. The general assumption is that glutamate is taken up into the 
brain endothelial cells via EAATs and subsequently transported across the luminal 
membrane to the blood, when the concentration gradient (cell-to-blood) favors cel-
lular efflux. Breakdown of glutamate in the blood thus creates a more favorable 
concentration gradient for the glutamate to exit the endothelial cells and thus accel-
erates the overall clearance from the brain ISF (Castillo et al. 2016). However, an 
alternative explanation could be that glutamate diffuses across the paracellular 
space between the brain endothelial cells, which is at least partly opened during 
stroke, traumatic brain injury, and subarachnoid hemorrhage (Chodobski et  al. 
2011; Fredriksson et al. 1987; Krueger et al. 2013; Doczi et al. 1986). Diffusion 
across the paracellular space would also be dependent on the brain-to-blood gluta-
mate concentration gradient, and breakdown of glutamate in the blood would have 
a similar beneficial effect in this mechanism. Interestingly, a recent study on the 
effect of blood glutamate scavenging in amyloid-beta toxicity showed that blood 
glutamate scavenging ameliorates the effects on long-term potentiation of both 
amyloid-beta and of the EAAT inhibitor, TBOA (Zhang et al. 2016). TBOA has 
previously been shown to cause neuronal damage by inhibiting glutamate uptake 
into astrocytes (Montiel et al. 2005), but the fact that this could be ameliorated by 
blood glutamate scavenging indicates that the brain-to-blood efflux is not depen-
dent on endothelial EAATs exclusively, since these would be inhibited by the 
TBOA in the ISF.
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6  Summary and Perspectives
Since the original formulation of the “brain glutamate efflux hypothesis” (Pardridge 
1979), a number of studies have demonstrated that excitatory amino acid transport-
ers are present in brain endothelial cells both in vitro and in vivo, although the sub-
type expression pattern varies among species. EAAT-mediated L-glutamate uptake 
into the endothelial cells constitutes the first step of the brain L-glutamate efflux; 
however, the following steps remain unclear. Saturable, low-affinity luminal uptake 
has been demonstrated, indicating the presence of an L-glutamate transporter in the 
luminal membrane of endothelial cells. Such a transporter could also in theory 
account for L-glutamate transport from endothelial cell interior to blood, given an 
L-glutamate concentration gradient from cell to blood which would favor this direc-
tion of transport. However, it has also recently been demonstrated that some metabo-
lism of L-glutamate occurs in the endothelial cells (and/or the astrocytes), followed 
by efflux of the metabolism products to the blood. Experimental evidence suggests 
that the glutamate-glutamine cycle does not play a role in the brain efflux of 
L-glutamate. However, metabolism to α-ketoglutarate via aminotransferases or glu-
tamate dehydrogenase is likely to take place both in endothelial cells and astrocytes. 
The relative contributions of transport and metabolism to the apparent L-glutamate 
efflux have not been fully elucidated and warrant further studies.
A number of in vivo studies have indicated that scavenging of blood glutamate 
could improve the outcome after stroke, subarachnoid hemorrhage, traumatic brain 
injury, and paraoxon intoxication. The mechanism suggested to be responsible for 
this phenomenon is transporter-mediated brain glutamate efflux, i.e., when blood 
glutamate concentrations are kept low, the concentration gradient for transporter- 
mediated brain-to-blood efflux is kept favorable for efflux, but as yet no firm in vivo 
evidence exists to support this point of view. A direction for future studies would be 
to focus on verifying the presence of EAATs on brain endothelium in vivo, determine 
EAAT subtype expression profile, identify the possible transporter responsible for 
the transport of L-glutamate across the luminal membrane, and investigate to what 
extent metabolism and transporter-mediated transport of L-glutamate contributes to 
the apparent L-glutamate efflux. This could lead to a clarification of the mechanisms 
behind the apparently beneficial effects of blood L-glutamate scavenging.
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